Abstract
In recent months, the entire world is facing a dramatic health emergency caused by the diffusion of a hitherto unknown coronavirus (SARS-CoV-2). Despite the efforts, the understanding of the many facets of the pandemic is still rather limited. In the present manuscript, we have monitored the evolution of the lethality rate in Italy by using the data collected over the last three months. Our data indicate that there is a striking correlation between the number of infected people of a certain week and the deaths of the following one. Despite the overall simplicity of the applied approach and its many approximations, the analysis of the Italian scenario provides some interesting insights into the pandemic. Indeed, we have found that the lethality rate is virtually unchanged over the last two months. This implies that the reduction of the deaths is strictly connected to the decrease of cases. Unfortunately, the present study does not support the idea that the virus potency has lowered in the last weeks, as our data demonstrate that the likelihood of a fatal outcome after the infection has not decreased in the recent outbreak evolution. Moreover, we show that the lethality rate is still very high in the country (≈13.5%). Since this number is remarkably higher if compared to the actual lethality estimates made worldwide, this finding suggests that the number of detected cases may be a gross underestimation of the actual infected people, likely due to the presence of a significant number of non-symptomatic or paucisymptomatic individuals in the population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The present activities have been performed in the framework of project 'RicErCa e sviluppO VERsus COVID19 in Campania RECOVER-COVID19' funded by the Campania Region
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This works is exempted from IRB/oversight
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used for the analyses are reported in the supplementary material and are available from the authors
